Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Terminado
Fase 1
ClinicalTrials.gov
A Phase 1, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies
INTERVENTIONAL
Inicio: 1 de oct de 2006
ID: NCT00381654
Reclutando
ClinicalTrials.gov
A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
OBSERVATIONAL
Inicio: 27 de ago de 2020
ID: NCT04529122
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers
INTERVENTIONAL
Inicio: 1 de abr de 2025
ID: NCT06864169
Completado
ClinicalTrials.gov
MEDICI - t(11;14) and BCL2 Expression in Patients With Multiple Myeloma: Prevalence, Stability Across Lines of Therapy and Concordance Across Sample Types
OBSERVATIONAL
Inicio: 7 de jul de 2021
ID: NCT04721002
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
INTERVENTIONAL
Inicio: 19 de abr de 2019
ID: NCT03596866
Terminado
Fase 2
ClinicalTrials.gov
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
INTERVENTIONAL
Inicio: 19 de nov de 2020
ID: NCT04581824
Desconocido
ClinicalTrials.gov
Treatment of Patients With Diffuse Large B-cell Non-Hodgkins Lymphoma in Stages I and II Without Risk Factors, Adapted to the Response Evaluated With PET CT (Positron Emission Computed Tomography)
OBSERVATIONAL
Inicio: 1 de jun de 2021
ID: NCT05078840
Completado
Fase 2
ClinicalTrials.gov
Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy
INTERVENTIONAL
Inicio: 29 de oct de 2018
ID: NCT03656718
Completado
Fase 3
ClinicalTrials.gov
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
INTERVENTIONAL
Inicio: 1 de jul de 2005
ID: NCT00123474
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.
INTERVENTIONAL
Inicio: 21 de nov de 2022
ID: NCT05456191
Completado
Fase 2
ClinicalTrials.gov
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
INTERVENTIONAL
Inicio: 1 de jun de 2008
ID: NCT00633789
Reclutando
Fase 3
ClinicalTrials.gov
A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
INTERVENTIONAL
Inicio: 25 de feb de 2025
ID: NCT06646276
Completado
Fase 3
ClinicalTrials.gov
An Open-label Study to Evaluate the Safety and Effect on Disease Progression and Overall Survival of Avastin Plus Taxane-based Chemotherapy in Patients With Locally Recurrent or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 1 de sept de 2006
ID: NCT00448591
Completado
Fase 3
ClinicalTrials.gov
A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment
INTERVENTIONAL
Inicio: 27 de nov de 2012
ID: NCT01702571
Desconocido
ClinicalTrials.gov
Effectiveness of a Decision Support System in Improving the Diagnosis and Screening Rate of Breast Cancer
INTERVENTIONAL
Inicio: 1 de nov de 2009
ID: NCT01336257
Reclutando
Fase 3
ClinicalTrials.gov
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)
INTERVENTIONAL
Inicio: 23 de jul de 2025
ID: NCT06758401
Completado
Fase 4
ClinicalTrials.gov
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
INTERVENTIONAL
Inicio: 10 de jun de 2013
ID: NCT01794793
Completado
Fase 3
ClinicalTrials.gov
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
INTERVENTIONAL
Inicio: 1 de oct de 2018
ID: NCT03631706
Terminado
Fase 3
ClinicalTrials.gov
A Randomized Withdrawal, Active- and Placebo-controlled, Double-blind, Multi-center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 (Tapentadol) Prolonged Release (PR*) in Subjects With Moderate to Severe Chronic Malignant Tumor-related Pain. *Prolonged Release and is the Recommended Nomenclature for Use in the European Union (EU). ER Means Extended Release and is the Recommended Nomenclature for Use in the United States of America (USA). "PR" is Synonymous With "ER" and is Interchangeable.
INTERVENTIONAL
Inicio: 1 de jun de 2007
ID: NCT00505414
Completado
Fase 3
ClinicalTrials.gov
Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma
INTERVENTIONAL
Inicio: 1 de abr de 2008
ID: NCT00631371
Anterior
1
...
64
65
66
...
434
Siguiente
Filtros